Etaracizumab

WikiDoc Resources for Etaracizumab
Articles
Most recent articles on Etaracizumab Most cited articles on Etaracizumab Review articles on Etaracizumab Articles on Etaracizumab in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Etaracizumab Images of Etaracizumab Photos of Etaracizumab Podcasts & MP3s on Etaracizumab Videos on Etaracizumab
Evidence Based Medicine
Cochrane Collaboration on Etaracizumab Bandolier on Etaracizumab TRIP on Etaracizumab
Clinical Trials
Ongoing Trials on Etaracizumab at Clinical Trials.gov Trial results on Etaracizumab Clinical Trials on Etaracizumab at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Etaracizumab NICE Guidance on Etaracizumab NHS PRODIGY Guidance FDA on Etaracizumab CDC on Etaracizumab
Books
Books on Etaracizumab
News
Etaracizumab in the news Be alerted to news on Etaracizumab News trends on Etaracizumab
Commentary
Blogs on Etaracizumab
Definitions
Definitions of Etaracizumab
Patient Resources / Community
Patient resources on Etaracizumab Discussion groups on Etaracizumab Patient Handouts on Etaracizumab Directions to Hospitals Treating Etaracizumab Risk calculators and risk factors for Etaracizumab
Healthcare Provider Resources
Symptoms of Etaracizumab Causes & Risk Factors for Etaracizumab Diagnostic studies for Etaracizumab Treatment of Etaracizumab
Continuing Medical Education (CME)
CME Programs on Etaracizumab
International
Etaracizumab en Espanol Etaracizumab en Francais
Business
Etaracizumab in the Marketplace Patents on Etaracizumab
Experimental / Informatics
List of terms related to Etaracizumab

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Etaracizumab (also known as etaratuzumab) is a humanized monoclonal antibody which it is used to treat metastatic melanoma and prostate cancer.